{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:20:10Z","timestamp":1778556010452,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.hoc.2019.11.001","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T20:23:25Z","timestamp":1577219005000},"page":"475-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing Symptom Burden in Myelodysplastic Syndrome\/Myeloproliferative Neoplasm Overlap Patients"],"prefix":"10.1016","volume":"34","author":[{"given":"Juan","family":"Garza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane Margret","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn M.","family":"Scherber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2019.11.001_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.11.001_bib2","doi-asserted-by":"crossref","first-page":"284706","DOI":"10.1155\/2015\/284706","article-title":"Impact of inflammation on myeloproliferative neoplasm symptom development","volume":"2015","author":"Geyer","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"7","key":"10.1016\/j.hoc.2019.11.001_bib3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2008.162","article-title":"Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia","volume":"22","author":"Emanuel","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2019.11.001_bib4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML-dysplastic versus proliferative type","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.hoc.2019.11.001_bib5","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML)","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2019.11.001_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2019.11.001_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2019.11.001_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2019.11.001_bib9","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2019.11.001_bib10","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2019.11.001_bib11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/asheducation-2015.1.264","article-title":"What's different about atypical CML and chronic neutrophilic leukemia?","volume":"2015","author":"Dao","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2019.11.001_bib12","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2019.11.001_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajh.24637","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2019.11.001_bib14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2006-05-022491","article-title":"High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count\u00a0> 600 x 109\/L) and ringed sideroblasts more than 15% considered as MDS\/MPD, unclassifiable","volume":"109","author":"Gattermann","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2019.11.001_bib15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1309\/AJCPT0B6VEQPRCOA","article-title":"Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings","volume":"135","author":"Gurevich","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2019.11.001_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.leukres.2008.08.022","article-title":"Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium","volume":"33","author":"Chan","year":"2008","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.hoc.2019.11.001_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2010.08525.x","article-title":"Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia","volume":"152","author":"Loh","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2019.11.001_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12881-015-0239-1","article-title":"Mutation in NRAS in familial Noonan syndrome\u2013\u2013case report and review of the literature","volume":"16","author":"Ekvall","year":"2015","journal-title":"BMC Med Genet"},{"issue":"10","key":"10.1016\/j.hoc.2019.11.001_bib19","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European working group on myelodysplastic syndromes in childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2019.11.001_bib21","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2019.11.001_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ajh.24983","article-title":"Chronic neutrophilic leukemia 2018: update on diagnosis, molecular genetics, prognosis, and management","volume":"93","author":"Elliott","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2019.11.001_bib23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2014.8","article-title":"Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy","volume":"28","author":"Dinardo","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.hoc.2019.11.001_bib24","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood.V128.22.3125.3125","article-title":"Myelodysplastic\/myeloproliferative neoplasms unclassified (MDS\/MPN-U) overlap: can we alter the natural history?","volume":"128","author":"Hendrix","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2019.11.001_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.leukres.2007.07.004","article-title":"Clinical and prognostic features of patients with myelodysplastic\/myeloproliferative syndrome categorized as unclassified (MDS\/MPD-U) by WHO classification","volume":"32","author":"Cannella","year":"2008","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.hoc.2019.11.001_bib26","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An international MDS\/MPN working group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.hoc.2019.11.001_bib27","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1182\/blood.V118.21.3839.3839","article-title":"The myeloproliferative neoplasm symptom assessment from (MPN-SAF) derived total symptom score (TSS): an international trial of 1433 patients with myeloproliferative neoplasms (MPNs)","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2019.11.001_bib28","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood.V122.21.4088.4088","article-title":"Sexuality challenges, intimacy, and MPN symptom burden: An analysis by the MPN quality of life international study group (MPN-QOL ISG)","volume":"122","author":"Geyer","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2019.11.001_bib29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.21671","article-title":"Fatigue in long-term breast carcinoma survivors: a longitudinal investigation","volume":"106","author":"Bower","year":"2006","journal-title":"Cancer"},{"issue":"33","key":"10.1016\/j.hoc.2019.11.001_bib30","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"Issue 1","key":"10.1016\/j.hoc.2019.11.001_bib31","first-page":"2273","article-title":"Therapeutic approaches in myelofibrosis and myelodysplastic\/myeloproliferative overlap syndromes","volume":"2016","author":"Sochacki","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"9","key":"10.1016\/j.hoc.2019.11.001_bib32","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.hoc.2019.11.001_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2019.11.001_bib34","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2011.36.1154","article-title":"Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?","volume":"29","author":"Bower","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2019.11.001_bib35","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.21234","article-title":"Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome","volume":"104","author":"Meyers","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2019.11.001_bib36","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Ayalew","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2019.11.001_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2019.11.001_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.1995.13.3.575","article-title":"Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma","volume":"13","author":"Seymour","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"42","key":"10.1016\/j.hoc.2019.11.001_bib39","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1523\/JNEUROSCI.3376-06.2006","article-title":"Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers","volume":"26","author":"Sparkman","year":"2006","journal-title":"J\u00a0Neurosci"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2019.11.001_bib40","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/blood-2018-99-112937","article-title":"Correlation between MPN-SAF TSS and EORTC QLQ-C30 scores in patients with PV: data from the reveal study","volume":"132","author":"Altomare","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2019.11.001_bib41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement","volume":"50","author":"Groenvold","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.hoc.2019.11.001_bib42","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1188\/18.ONF.653-664","article-title":"Symptoms, mobility and function, and quality of life in adults with acute leukemia during initial hospitalization","volume":"45","author":"Bryant","year":"2018","journal-title":"Oncol Nurs Forum"},{"issue":"8","key":"10.1016\/j.hoc.2019.11.001_bib43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","article-title":"Measuring health-related quality of life in leukemia: the functional assessment of cancer therapy\u2013\u2013leukemia (FACT-leu) questionnaire","volume":"15","author":"Cella","year":"2012","journal-title":"Value Health"},{"issue":"21","key":"10.1016\/j.hoc.2019.11.001_bib44","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood.V116.21.3827.3827","article-title":"Reliability and validity of the FACT-an in patients with low or int-1-risk myelodysplastic syndromes with deletion 5q","volume":"116","author":"Brandenburg","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2019.11.001_bib45","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2019.11.001_bib56","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood-2018-99-119476","article-title":"Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia","volume":"132","author":"Dao","year":"2018","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881930156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881930156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:12:57Z","timestamp":1760184777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985881930156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S088985881930156X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2019.11.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Symptom Burden in Myelodysplastic Syndrome\/Myeloproliferative Neoplasm Overlap Patients","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2019.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}